Literature DB >> 20877417

Chemotherapy: Gemcitabine alone or plus cisplatin for biliary tract cancer?

Werner Scheithauer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20877417     DOI: 10.1038/nrclinonc.2010.130

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

Authors:  E Van Cutsem; M Dicato; N Arber; J Berlin; A Cervantes; F Ciardiello; A De Gramont; E Diaz-Rubio; M Ducreux; R Geva; B Glimelius; R Glynne Jones; A Grothey; T Gruenberger; D Haller; K Haustermans; R Labianca; H J Lenz; B Minsky; B Nordlinger; A Ohtsu; N Pavlidis; P Rougier; W Schmiegel; C Van de Velde; H J Schmoll; A Sobrero; J Tabernero
Journal:  Ann Oncol       Date:  2010-06       Impact factor: 32.976

2.  Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.

Authors:  R Hitt; D Castellano; M Hidalgo; R García-Carbonero; M Peña; A Brandariz; J M Millán; J J Alvarez Vincent; H Cortés-Funes
Journal:  Ann Oncol       Date:  1998-12       Impact factor: 32.976

3.  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.

Authors:  B Glimelius; K Hoffman; P O Sjödén; G Jacobsson; H Sellström; L K Enander; T Linné; C Svensson
Journal:  Ann Oncol       Date:  1996-08       Impact factor: 32.976

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

Authors:  L Crinò; G Scagliotti; M Marangolo; F Figoli; M Clerici; F De Marinis; F Salvati; G Cruciani; L Dogliotti; F Pucci; A Paccagnella; V Adamo; G Altavilla; P Incoronato; M Trippetti; A M Mosconi; A Santucci; S Sorbolini; C Oliva; M Tonato
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

6.  Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.

Authors:  A Tannapfel; F Sommerer; M Benicke; A Katalinic; D Uhlmann; H Witzigmann; J Hauss; C Wittekind
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

7.  Identification of novel cellular targets in biliary tract cancers using global gene expression technology.

Authors:  Donna E Hansel; Ayman Rahman; Manuel Hidalgo; Paul J Thuluvath; Keith D Lillemoe; Richard Schulick; Ja-Lok Ku; Jae-Gahb Park; Kohje Miyazaki; Raheela Ashfaq; Ignacio I Wistuba; Ram Varma; Lesleyann Hawthorne; Joseph Geradts; Pedram Argani; Anirban Maitra
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

8.  Synergistic interaction between cisplatin and gemcitabine in vitro.

Authors:  A M Bergman; V W Ruiz van Haperen; G Veerman; C M Kuiper; G J Peters
Journal:  Clin Cancer Res       Date:  1996-03       Impact factor: 12.531

9.  Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.

Authors:  F Eckel; R M Schmid
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.